Last reviewed · How we verify
cereport
cereport is a Small molecule drug developed by Children's Oncology Group. It is currently in Phase 1 development. Also known as: labradimil, IND #60315.
Cereport is being studied in clinical trials for various conditions, including brain and central nervous system tumors, meningitis, and HIV infections, in combination with carboplatin and radiation therapy. The exact mechanism of cereport is not specified in the provided information, but it is being investigated in clinical trials for these conditions.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | cereport |
|---|---|
| Also known as | labradimil, IND #60315 |
| Sponsor | Children's Oncology Group |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas (PHASE1)
- Lobradimil and Carboplatin in Treating Children With Brain Tumors (PHASE2)
- A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors (PHASE1)
- The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cereport CI brief — competitive landscape report
- cereport updates RSS · CI watch RSS
- Children's Oncology Group portfolio CI
Frequently asked questions about cereport
What is cereport?
Who makes cereport?
Is cereport also known as anything else?
What development phase is cereport in?
Related
- Manufacturer: Children's Oncology Group — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: labradimil, IND #60315
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing